Bioretec Oy Announces Updated Sales‑Margin Target and Reporting Methodology
Bioretec Oy, a Finnish medical‑device company listed on the Frankfurt Stock Exchange, has issued a formal update regarding its 2026‑2028 financial objectives and the methodology it will use to report sales‑margin figures.
Change to Reporting Methodology
From the first quarter of the current year, Bioretec will transition to an industry‑standard reporting practice that uses adjusted gross margin (AGM) rather than the previously reported gross margin. The new approach will exclude costs such as sales commissions and fixed external services that were previously deducted from revenue, providing a clearer picture of the profitability of the company’s implant sales before marketing and commercialization expenses.
Updated Financial Targets
The updated AGM methodology will also affect the company’s strategic financial targets for the 2026‑2028 period:
| Metric | Original Definition | Updated Definition |
|---|---|---|
| Revenue Target | 10 million EUR by 2028 | 10 million EUR by 2028 (unchanged) |
| Sales‑Margin Target | Not specified | >70 % adjusted gross margin over the strategy period |
These targets are intended to enhance transparency and align Bioretec’s reporting with sector norms.
Upcoming Quarterly Results
Bioretec will release its first‑quarter results on Friday, 15 May 2026. Investors and analysts will be able to assess the company’s performance against the newly defined targets once those figures are published.
Company Background
Bioretec Oy develops bioabsorbable and bioresorbable implants for both pediatric and adult orthopaedics, serving a global customer base. The company’s market capitalization is approximately 16 million EUR, and its shares trade in euros on the Frankfurt Stock Exchange.
All information presented is sourced from the company’s official announcements and related financial news reports dated 13 May 2026.
